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Ibrutinib is a potent inhibitor of Bruton’s tyrosine kinase (BTK). Studies published in the New England Journal
of Medicine report that patients with chronic lymphocytic leukemia (CLL) have durable responses to ibrutinib,
but they also describe the advent of bypass mutations that result in ibrutinib resistance and progressive
disease.Signaling through the B cell receptor
(BCR) can promote tumor cell survival in
B cell malignancies, including chronic
lymphocytic leukemia (CLL), mantle cell
lymphoma (MCL), and the activated B
cell-like (ABC) subtype of diffuse large
B cell lymphoma (DLBCL). The BCR
consists of immunoglobulin heavy (IgH)
and light (IgL) chains coupled to a
CD79A-CD79B heterodimer that trans-
duces signals by engaging downstream
nonreceptor kinases, including Bruton’s
tyrosine kinase (BTK) (Young and Staudt,
2013). These kinases offer a wealth of
therapeutic targets, and drugs targeting
SYK, BTK, and phosphatidylinositol 3-ki-
nase (PI3K) are in clinical trials to evaluate
their efficacy against a variety of human
lymphomas.
Ibrutinib (PCI-32765, Imbruvica) is an
irreversible inhibitor of BTK that works
by forming a covalent bond with cysteine
481 (C481) in the BTK active site,
rendering the drug potent and highly
selective, thereby limiting side effects.
Several clinical trials are now evaluating
ibrutinib in human lymphomas, and thedrug has been granted breakthrough sta-
tus by the US Food and Drug Administra-
tion for the treatment of refractory MCL
and high-risk CLL. Because activating
mutations in BTK have not been observed
in these lymphomas, it is likely that up-
stream signaling from the BCR is the
culprit.
BCR expression is obligatory in normal
B cells and most malignant B cells. In
CLL, analysis of the antigen recognition
portion of the BCR revealed preferential
usage of a small subset of Ig variable
gene segments, suggesting that the
BCRs may react with an antigen. In sup-
port of this notion, different CLL and
MCL patients can have ‘‘stereotypic’’
BCRs with virtually identical antigen
recognition sites (Agathangelidis et al.,
2012). The first direct evidence for BCR-
dependent survival signaling was ob-
tained in ABC DLBCL (Davis et al.,
2010). RNA interference screening re-
vealed that BCR components and down-
stream signaling effectors (SYK, BTK,
and PLCg2) are required for ABC DLBCL
cell survival. Microscopy revealed BCRclusters on the surface of ABC DLBCL
cells that are similar to those induced by
antigen engagement of the BCR in normal
B cells. Recurrent gain-of-function muta-
tions in CD79A and CD79B augment
BCR signaling in a subset of ABC DLBCL
cases, providing genetic evidence that
the BCR pathway is important in the path-
ogenesis of this lymphoma subtype. The
‘‘chronic active’’ form of BCR signaling
in ABC DLBCL is sensitive to ibrutinib
and therefore may be mechanistically
similar to BCR signaling in CLL and MCL
(Figure 1).
Three reports in the New England Jour-
nal of Medicine examined ibrutinib treat-
ment in CLL patients. The first study
evaluated ibrutinib monotherapy in pa-
tients with relapsed and high-risk CLL
versus ofatumumab, an anti-CD20 anti-
body that is the current standard therapy
for these patients. Ibrutinib produced a
70% response rate compared with only
21% for ofatumumab, and ibrutinib was
also superior to ofatumumab with respect
to progression-free and overall survival
(Byrd et al., 2014).ell 26, July 14, 2014 ª2014 Elsevier Inc. 11
Figure 1. B Cell Receptor Signaling in Malignant B Cells
Chronic active BCR signaling is shown. Ibrutinib is shown to inhibit BTK. Red asterisks denote signaling effectors that are the target of ibrutinib resistance
mutations in CLL patients.
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the malignant clone in CLL, and the latter
two studies describe resistance mecha-
nisms in CLL patients who had progres-
sive disease while on ibrutinib therapy
(Woyach et al., 2014; Furman et al.,
2014). Whole-exome sequencing of pre-
treatment and relapse samples from six
CLL patients identified a mutation that
changed the cysteine at BTK position
481 to serine (C481S) in five of the six
patients. BTK C481S prevents the drug
from covalently binding BTK, rendering
cells substantially more resistant to ibruti-
nib. By contrast, cells with wild-type or
mutant BTK were equally sensitive to
dasatinib, a reversible BTK inhibitor that
does not act on C481. Additionally, CLL
cells from two patients had gain-of-func-
tion mutations targeting PLCg2, a direct
downstream target of BTK phosphoryla-
tion. These data imply that the efficacy
of ibrutinib in CLL is due to inhibition of
BTK in the malignant cells rather than
other potential effects on nonmalignant
cells. It is unclear at present how fre-
quently these mutations cause ibrutinib
resistance in CLL, and it seems likely
that other resistance mechanisms remain
to be discovered.
These results are reminiscent of resis-
tance mutations that occur with other
tyrosine kinase inhibitors, including the12 Cancer Cell 26, July 14, 2014 ª2014 ElsevT315I mutation in BCR-ABL that disrupts
a hydrogen bond with imatinib (Gorre
et al., 2001) and the T790M mutation in
EGFR that sterically excludes erlotinib
from the active site (Pao et al., 2005). A
variety of next-generation inhibitors have
been developed to circumvent these mu-
tations. Similarly, ATP-competitive BTK
inhibitors could be developed that do
not require C481 for activity, although it
will be a challenge to identify molecules
with the potency of ibrutinib. The detec-
tion of PLCG2 mutations may indicate
that a CLL clone could bypass the need
for BTK activity altogether. Perhaps
arguing against this, one CLL case had
both PLCG2 and BTK C481S mutations.
One wonders about the origins of the
BTK and PLCG2 mutations. Are these
mutations present because of the low
ongoing rate of mutagenesis within the
tumor? Substantial intraclonal diversity
has been reported in CLL and other malig-
nancies, and it is known that standard
cytotoxic chemotherapies promote the
outgrowth of tumor subclones (Landau
et al., 2013). Alternatively, mutations in
BTK andPLCG2may confer gain-of-func-
tion phenotypes that lead to their enrich-
ment prior to therapy. Of note, one of the
PLCG2 mutations in CLL (S707Y) was
previously identified as a germline-en-
coded mutation that causes an autoin-ier Inc.flammatory disorder because of its ability
to enhance synthesis of inositol trisphos-
phate and promote calcium flux after
receptor stimulation (Zhou et al., 2012).
Two other PLCG2 mutants in CLL
(R665W and L845F) increase calcium
flux in response to IgM crosslinking
(Woyach et al., 2014), raising the possibil-
ity that they augment chronic active BCR
signaling and increase the abundance
of the subclone prior to therapy by
increasing tumor cell proliferation and/or
survival.
Roughly 20% of patients with CLL have
persistent lymphocytosis during ibrutinib
therapy, and most patients are likely
to have residual tumor cells, providing
ample opportunity for the emergence of
resistant subclones. This necessitates
the development of drug combinations
that limit the avenues available to the
malignant cells for proliferation and sur-
vival. A recent chemical genomics screen
in ABC DLBCL revealed that ibrutinib syn-
ergizes with inhibitors of SYK, BCL2, and
multiple components of the PI3K pathway
(Mathews Griner et al., 2014). The PI3K
delta inhibitor idelalisib and the BCL2 in-
hibitor navitoclax have already shown sin-
gle agent activity in CLL, supporting their
evaluation in combination with ibrutinib.
Thus, although CLL may have won the
battle with ibrutinib in some patients, our
Cancer Cell
Previewsever-increasing armamentarium of drugs
targeting the BCR pathway should allow
us to win the war.
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